Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiperstat PK in Hepatic Impairment
NCT05751759Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF), chronic obstructive pulmonary disease (COPD) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 7 more. Started Mar 2023; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic obstructive pulmonary disease (COPD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05751759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751759.